JNJ stock forecast, quote, news & analysis

Key Takeaways

• Johnson & Johnson shares have climbed approximately 6.7% over the past 30 days, building on a broader multi-month recovery from late-April lows.
• Guggenheim raised its price target to $270 and named JNJ a top large-cap biopharma pick, citing stronger-than-expected prescription trends for Tremfya, Caplyta, and Erleada.
• The company is scheduled to report second-quarter 2026 earnings on July 15, with consensus estimates at $24.96 billion in revenue and $2.85 EPS.
• Positive clinical trial data for TALVEY and IMAAVY, alongside a $55 billion U.S. manufacturing investment plan, reinforce the long-term growth narrative.
• Persistent talc-related litigation remains a key risk, with an Illinois appellate court recently upholding a $45 million mesothelioma verdict.

Current Market Snapshot

Johnson & Johnson shares closed at $256.98 on July 10, 2026, positioning the healthcare giant near the upper end of its recent trading range. The stock trades above both its 50-day moving average of approximately $237 and its 200-day moving average of roughly $233, reflecting sustained upward momentum. With a market capitalization of $619 billion, a P/E ratio of about 29.7, and a beta of just 0.24, JNJ continues to attract investors seeking defensive exposure combined with growth. The company's recently increased quarterly dividend of $1.34 per share — representing a 3.1% raise from $1.30 — delivers an annualized yield of roughly 2.1%, reinforcing its 55-year track record of consecutive dividend increases.

Johnson & Johnson (JNJ) Business Overview and Competitive Position

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, operating through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division, anchored by the Janssen pharmaceutical organization, develops and markets prescription therapies across immunology, oncology, neuroscience, infectious disease, and cardiovascular medicine. Key products include Tremfya, Darzalex, Stelara, Carvykti, and Spravato. The MedTech segment covers surgical technologies, orthopedics, vision products — including the ACUVUE contact lens franchise — and interventional solutions. J&J's competitive strength lies in its 28 platforms generating at least $1 billion each in annual revenue, a deep late-stage pipeline, and the financial capacity to invest heavily in R&D and manufacturing. CEO Joaquin Duato has publicly expressed confidence in the company's trajectory, pointing to a $55 billion planned investment in U.S. manufacturing and R&D over the next four years.

Recent Developments Driving JNJ

Several developments have shaped investor sentiment over the past month. On June 26, Guggenheim raised its JNJ price target to $270 from $266 while reiterating a Buy rating and designating the stock a top pick in large-cap biopharma. The firm highlighted robust prescription data for Tremfya, Caplyta, and Erleada, which exceeded internal forecasts. Guggenheim expects JNJ to report second-quarter revenues of $25.48 billion and EPS of $2.87, above the Street consensus, when the company releases results on July 15.

On the clinical front, Johnson & Johnson reported positive Phase 3 MonumenTAL-3 data for TALVEY in relapsed/refractory multiple myeloma and encouraging Phase 2/3 ENERGY study results for IMAAVY in warm autoimmune hemolytic anemia. The company also expanded U.S. availability of its TECNIS PureSee intraocular lens and launched the Dual Energy THERMOCOOL SMARTTOUCH SF platform in Europe. Separately, JNJ announced a more than $1 billion investment in its Jacksonville, Florida operations to expand ACUVUE contact lens manufacturing, packaging, and distribution.

Multiple Wall Street firms have adjusted their outlooks. HSBC initiated with a $290 price target and Buy rating. Citigroup raised its target to $298, while Goldman Sachs and Morgan Stanley maintain bullish stances at $275 and $284, respectively. The consensus analyst rating stands at Moderate Buy with an average price target near $258.

On the legal side, an Illinois appellate court upheld a $45 million mesothelioma verdict against Johnson & Johnson and Kenvue, keeping talc-related asbestos litigation in focus. However, JNJ continues to pursue a comprehensive resolution through its prepackaged reorganization plan involving approximately $6.475 billion in present value for ovarian cancer talc claimants, covering 99.75% of pending suits.

Trending AI Robots

Investors seeking data-driven, automated trading strategies may find value in Tickeron's Trending AI Robots page. This curated section showcases a selection of top-performing AI-powered trading bots from a universe of hundreds that actively trade thousands of tickers. Each bot employs distinct strategies, timeframes, and performance metrics — ranging from short-term swing trading to longer-duration trend following — allowing users to identify approaches aligned with their own trading objectives. The page serves as a practical entry point for those exploring how algorithmic and AI-driven methodologies can complement traditional research when navigating stocks like JNJ.

2026 Outlook and What Investors Should Watch

Looking ahead, several factors will likely shape Johnson & Johnson's stock performance through the remainder of 2026. The July 15 Q2 earnings report will be the most immediate catalyst, with investors watching for revenue growth across the immunology and oncology portfolios, updates on the Icotyde and Inlexzo launches, and any adjustments to full-year guidance currently set at $11.45 to $11.65 EPS. Prescription trend data for recently launched therapies and the pace of biosimilar erosion for Stelara will also be scrutinized.

Beyond earnings, the resolution of talc litigation remains a material swing factor. Successful confirmation of the prepackaged reorganization plan could remove a long-standing overhang, while adverse rulings may add pressure. On the operational side, the $55 billion U.S. investment program signals management's confidence in long-term demand, particularly in biologics manufacturing capacity for oncology and immunology. Additionally, any progress on TALVEY and IMAAVY regulatory filings could provide incremental upside. Macroeconomic developments, including interest rate policy and healthcare spending trends, will continue to influence institutional positioning in large-cap defensive names like JNJ.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.